Resources

Guidance: Drug formulary dose cap overrides those set at a regimen level

An explanation of the iQemo settings hierarchy, from drug-formulary to drug-level, and how that relates to dose capping.

Photograph of a clinical user operating a touch-screen tablet device
Photograph of a clinical user operating a touch-screen tablet device

In iQemo there is a hierarchy of control settings, so that those made at regimen level will override those set at a formulary level. This Hierarchy is present for nearly all features where the drug formulary level is the top level, which the regimen level then overrides. Within the regimen itself the regimen level is the top level, however the template level sits below that. The template overrides the regimen level. Finally within the template there is the drug level. The drug level overrides the template level. So, at each more-specific level the settings will override those set at the previous, less-specific level.

Dose caping

The one exception is dose capping. This logic is in place with the intention of aligning drug doses as defined by the SmPC for the drug. However users need to be aware that a hazard exists when, if the intention is to limit a drug by setting a cap at the regimen level, this will be overridden if a higher dose cap is set at the formulary level. The harm would be that a patient could receive a higher dose than intended. Applying the two-step verification as part of the regimen build process will mitigate this risk. A future iteration of iQemo will revisit the logic likely to remove formulary level controls for dose capping.

About iQ HealthTech

iQ HealthTech was established in 2011 by a founding-team of software developers and a practicing consultant oncologist. With a team of subject experts working across design, development, implentations and customer success, the company develops people-centric technology with the goal of improving patient outcomes, everywhere. The company delivers innovative Saas and standalone platforms, including iQemo – the industry-leading, end-to-end chemotherapy prescribing and management platform used by NHS and private hospitals in the UK, and a growing number of hospitals worldwide. Learn more

We’re working on an innovative future for healthcare technology

Sign up to our newsletter and stay updated with industry-leading advice, insight and more…

Thank you! Your submission has been received!
Sorry, something went wrong while submitting the form.

About iQemo

iQemo, from iQHealthTech, provides specialist chemotherapy prescribing. A complete end-to-end solution that includes predefined regimens, prescribing, scheduling and dispensing, through to chemotherapy administration and reporting. iQemo is used in NHS Trusts and private hospitals in the UK, and in a growing number of hospitals worldwide. Learn More

About iQ HealthTech

iQ HealthTech was established in 2011 by a founding-team of software developers and a practicing consultant oncologist. With a team of subject experts working across design, development, implentations and customer success, the company develops people-centric technology with the goal of improving patient outcomes, everywhere. Learn more

Would you like more information about iQemo?

We'd love to discuss how iQemo could support your organisation, people and patients.

Get in touch